Kidney cancer, or renal cancer, arises when abnormal cells in the kidneys grow uncontrollably and form tumors, disrupting normal kidney function. The most prevalent type is renal cell carcinoma (RCC), accounting for approximately 90% of cases, while less common forms include transitional cell carcinoma and Wilms tumor, the latter primarily affecting children. Staging of kidney cancer follows the TNM system, assessing the size and extent of the tumor (T), involvement of regional lymph nodes (N), and distant spread (metastasis, or M). In Stage 1, tumors are 7 cm or smaller and confined to the kidney, offering a high survival rate with early treatment. Stage 2 involves tumors larger than 7 cm that remain within the kidney and still carry a favorable prognosis if addressed promptly. Stage 3 indicates local advancement, with cancer spreading to nearby lymph nodes or major blood vessels like the renal vein or vena cava, and is associated with a higher risk of recurrence. Stage 4, the most advanced stage, occurs when the cancer spreads to distant organs such as the lungs, bones, liver, or brain, or to multiple lymph nodes, making it challenging to cure but potentially manageable with systemic treatments such as targeted therapy and immunotherapy.

Kidney cancer risk is influenced by a combination of non-modifiable and modifiable factors, as well as some potential contributors that continue to be studied. Non-modifiable risk factors include age, with risk rising significantly after 50; gender, as men are more commonly affected than women; and race, with African Americans and Native Americans showing slightly elevated risk. A family history of kidney cancer and inherited genetic conditions such as von Hippel-Lindau disease, hereditary papillary renal cell carcinoma, and Birt-Hogg-Dub syndrome also heighten susceptibility due to underlying genetic predispositions. Modifiable risk factors offer opportunities for prevention, including smoking, which significantly increases risk; obesity, which may alter hormone levels and promote tumor growth; and high blood pressure, a well-established but often overlooked contributor. Occupational exposures to hazardous substances like cadmium, asbestos, and organic solvents further increase risk, especially in industrial settings. Additionally, chronic kidney disease, particularly cases requiring long-term dialysis, is strongly associated with kidney cancer. Poor dietary habits, such as consuming high amounts of processed meats and inadequate fruits and vegetables, may also contribute. Other potential risk factors include long-term use of certain pain medications like ibuprofen or acetaminophen and excessive alcohol consumption, though the latter has less conclusive evidence. Understanding and addressing modifiable risks, especially in high-risk individuals, can play a key role in reducing the incidence of kidney cancer.

Kidney cancer (renal cancer) often develops silently, with few or no symptoms in its early stages, making it difficult to detect until it has progressed. As the tumor grows or spreads, several symptoms may emerge, the most common being blood in the urine (hematuria), which can cause the urine to appear pink, red, or cola-colored-though it may be intermittent and easily missed. Persistent pain in the side or lower back, unrelated to injury, and a lump or mass in the abdomen or side that may be palpable during a physical exam are also common warning signs. Systemic symptoms such as unexplained weight loss, persistent fatigue, and loss of appetite may develop, often indicating more advanced disease. Some individuals may experience fevers that come and go without signs of infection, or anemia, which results in low red blood cell counts and leads to fatigue, weakness, or pale skin. Additionally, swelling in the legs or ankles can occur if the cancer impairs kidney function or causes obstruction in blood vessels. Because many of these symptoms overlap with other non-cancerous conditions, prompt medical evaluation and diagnostic testing are essential for accurate diagnosis and timely treatment.

The diagnosis of kidney cancer (renal cancer) involves a comprehensive approach combining clinical assessment, imaging studies, laboratory evaluations, and occasionally tissue biopsy to confirm the presence and extent of disease. It begins with a medical history and physical examination, where the doctor will review symptoms, assess risk factors such as smoking or family history, and physically check for any abdominal masses, tenderness, or swelling. Imaging tests are central to diagnosis: an ultrasound may be used first to differentiate between solid tumors and benign cysts, while a CT scan is the most effective and commonly used method, providing detailed images of the kidneys and surrounding tissues to evaluate tumor size, location, and potential spread. An MRI may be used if CT results are inconclusive or if contrast dye is contraindicated. To assess distant spread, a chest X-ray or CT scan of the chest can evaluate lung involvement, and a bone scan may be ordered if there are signs of bone metastasis. Although there are no definitive blood or urine tests to diagnose kidney cancer, urinalysis can detect blood in the urine, and blood tests such as a complete blood count (CBC), kidney function tests, and liver function tests help assess overall health and organ function. A biopsy, where a small tissue sample is extracted and examined under a microscope, may be used in select cases particularly when imaging is inconclusive or for small tumors where the treatment approach depends on confirming malignancy. After diagnosis, staging is performed using the TNM system to determine the extent of cancer, from Stage I (localized) to Stage IV (metastatic). Advanced imaging like a PET scan may be used to detect distant metastases, and biopsies of metastatic sites may be done to confirm the spread of the disease. Accurate staging is critical for guiding treatment decisions and predicting outcomes.

Kidney cancer treatment varies based on the stage, tumor size, location, and patient health, with surgery being the primary approach for localized disease; partial nephrectomy removes the tumor while preserving kidney function for smaller tumors, whereas radical nephrectomy involves complete kidney removal for larger or more invasive cancers, often performed minimally invasively for faster recovery. For advanced or metastatic cases, targeted therapies such as tyrosine kinase inhibitors (e.g., sunitinib) and mTOR inhibitors, along with immunotherapies like immune checkpoint inhibitors (nivolumab, pembrolizumab), play a crucial role in controlling disease progression. Radiation therapy is typically reserved for palliative care to alleviate symptoms such as bone pain or brain metastases. Ablation techniques like cryoablation and radiofrequency ablation offer non-surgical tumor destruction for patients unsuitable for surgery. Active surveillance may be appropriate for small, slow-growing tumors in older or frail patients, with treatment initiated only upon progression. For metastatic cancer, combination therapies and clinical trials provide additional options, while palliative care focuses on symptom relief, pain management, and quality of life enhancement.

Reducing the risk of kidney cancer requires a comprehensive approach centered on healthy lifestyle choices and minimizing exposure to known environmental and occupational hazards. Smoking cessation is paramount, as tobacco use significantly increases the risk, and support through counseling or medication can aid quitting. Maintaining a healthy weight through a balanced diet rich in fruits, vegetables, whole grains, and lean proteins while limiting processed meats, red meats, saturated fats, and sugars helps reduce obesity-related risk factors. Regular physical activity, such as walking or cycling for at least 30 minutes most days, not only aids weight control but also lowers the risk of many cancers. Managing high blood pressure is crucial, involving dietary modifications to reduce salt intake, consistent exercise, and adherence to prescribed medications. Avoiding or minimizing exposure to carcinogenic chemicals like asbestos, cadmium, and organic solvents especially in high-risk occupational settings is essential, alongside following workplace safety protocols and using protective equipment. Long-term or excessive use of nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided or monitored due to potential kidney damage. Staying adequately hydrated supports kidney function, with a daily goal of at least eight glasses of water, while moderating alcohol consumption reduces potential risks. Individuals with chronic kidney disease require careful management and regular monitoring to prevent progression and complications. Genetic predispositions or family history of kidney cancer warrant consultation for genetic counseling and regular screening through imaging modalities such as ultrasound or CT scans to enable early detection. Additionally, avoiding anabolic steroid misuse and maintaining awareness of occupational risks in industries like metalworking or chemical manufacturing further diminish cancer risk. Ultimately, staying informed about kidney cancers risk factors and symptoms empowers individuals to seek timely medical evaluation, facilitating early diagnosis and improving treatment outcomes.

Research on kidney cancer is focused on improving early detection, understanding genetic factors, and developing more effective treatments.

1. What is kidney cancer? Kidney cancer is a type of cancer that starts in the kidneys, most commonly renal cell carcinoma (RCC). It happens when kidney cells grow uncontrollably, forming tumors. 2. What are the early signs of kidney cancer? Many people dont experience symptoms early on, but possible signs include blood in the urine, lower back pain on one side, a lump or mass in the lower back or abdomen, unexplained weight loss, fatigue, and high blood pressure. 3. What causes kidney cancer? The exact cause is unknown, but risk factors include smoking, high blood pressure, obesity, family history of kidney cancer, chronic kidney disease or dialysis, and exposure to toxic chemicals such as cadmium and asbestos. 4. How is kidney cancer treated? Treatment typically involves surgery to remove part or all of the kidney, targeted therapy to block cancer growth signals, immunotherapy to boost the immune system, radiation therapy to relieve symptoms in advanced cases, and chemotherapy in certain aggressive cancers. 5. Can kidney cancer be cured? Early-stage kidney cancer (Stages 1 and 2) has a high cure rate with surgery. Advanced kidney cancer (Stages 3 and 4) is more difficult to cure but can often be managed with targeted therapies and immunotherapy.